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Abstract
Background: The Ryan White HIV/AIDS Care Act (now the Treatment Modernization Act; Ryan White Program, or RWP) is a
source of federal public funding for HIV care in the United States. The Health Services and Resources Administration requires
that facilities or providers who receive RWP funds ensure that HIV health services are accessible and delivered according to
established HIV-related treatment guidelines. We used data from population-based samples of persons in care for HIV
infection in three states to compare the quality of HIV care in facilities supported by the RWP, with facilities not supported
by the RWP.
Methodology/Principal Findings: Within each area (King County in Washington State; southern Louisiana; and Michigan), a
probability sample of patients receiving care for HIV infection in 1998 was drawn. Based on medical records abstraction,
information was collected on prescription of antiretroviral therapy according to treatment recommendations, prescription
of prophylactic therapy, and provision of recommended vaccinations and screening tests. We calculated population-level
estimates of the extent to which HIV care was provided according to then-current treatment guidelines in RWP-supported
and non-RWP-supported facilities. For all treatment outcomes analyzed, the compliance with care guidelines was at least as
good for patients who received care at RWP-supported (vs non-RWP supported) facilities. For some outcomes in some
states, delivery of recommended care was significantly more common for patients receiving care in RWP-supported
facilities: for example, in Louisiana, patients receiving care in RWP-supported facilities were more likely to receive indicated
prophylaxis for Pneumocystis jirovecii pneumonia and Mycobacterium avium complex, and in all three states, women
receiving care in RWP-supported facilities were more likely to have received an annual Pap smear.
Conclusions/Significance: The quality of HIV care provided in 1998 to patients in RWP-supported facilities was of equivalent
or better quality than in non-RWP supported facilities; however, there were significant opportunities for improvement in all
facility types. Data from population-based clinical outcomes surveillance data can be used as part of a broader strategy to
evaluate the quality of publicly-supported HIV care.
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Introduction
Since 1990, the Federal Government, through Title XXVI of
the Public Health Service (PHS) Act as currently amended by the
Ryan White HIV/AIDS Treatment Modernization Act of
2006[1] (Ryan White Program, or RWP), has provided funding
to states, cities, and nonprofit organizations to improve the quality
and availability of medical care and supportive services for low-
income, uninsured, and underinsured individuals and families
affected by HIV/AIDS. Administered through the Health
Resources and Services Administration (HRSA), RWP funds are
provided directly to healthcare facilities (through Part C grants to
Community Health Centers, University-affiliated medical centers,
hospitals, or other community-based health care settings) or may
support care in facilities indirectly, through grants provided to
state health departments and local health departments in eligible
metropolitan areas (EMAs) or transitional grant areas (TGAs).
The legislation which provides these funds for HIV care and
services also requires that service providers establish quality
management programs to assess the extent to which HIV health
services provided to patients under the grant are consistent with the
most recent PHS guidelines for the treatment of HIV/AIDS and
related opportunistic infections [1]. To monitor quality of care,
HRSA provides technical assistance to grant recipients for quality
improvement [2], and grantees can use a proportion of their awards
to implement a clinical quality management program [1].
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3250Recently, the Institute of Medicine recommended that quality of
care should be measured at the broader population level, that
population-based methods should be used for such evaluations, and
that information on quality of care with respect to both prophylaxis
and treatment should be measured [3]. Representative data on
patients in care will soon be available in the United States [4]; we
used data from a pilot probability sample of patients in care for HIV
infection in 1998 to provide historical information about the quality
of care provided in facilities supported by the RWP to that in non-
RWP-supported facilities, to provide baseline data for comparison
with future analyses of quality of care from population-based
systems, and to illustrate the use of population-based clinical
outcomes surveillance data for describing quality of care.
Methods
The Survey of HIV Disease and Care (SHDC) project was a
pilot project to develop methods for the use of population-based
sampling of persons receiving care for HIV infection as a method
of HIV clinical outcomes surveillance. The methods have been
previously reported [5]. The three participating health jurisdic-
tions (‘‘study sites’’) were chosen by a competitive application
process to CDC. Project staff at each study site first defined a
geographic area for inclusion in the study; the geographic areas
were the entire state of Michigan, health regions 1,2,3,4, and 9 in
Louisiana (southern Louisiana, including New Orleans and Baton
Rouge), and King County (including Seattle) in Washington State.
The chosen geographic areas within each state reflected a number
of considerations, including jurisdiction for public health surveil-
lance, available resources, and distribution of AIDS prevalence
within the area. Health department staff in each study site then
constructed a sampling frame of HIV care facilities within the
defined geographic area, using data on health care providers and
facilities who had reported diagnosing or caring for persons with
HIV infection to the health department as part of HIV/AIDS
surveillance, and other data sources. Facilities that provided no
clinical care, such as HIV counseling and testing facilities, were
excluded. Facilities could represent a single provider, a group of
providers sharing a common medical records system, or some
other clinic with a single medical records system. Facilities were
classified based on size of HIV patient load (small, medium, or
large), urban vs. rural location, and on whether or not the provider
or facility received RWP support–either directly from HRSA
under Part C (formerly Title III), or indirectly through a state or
local health department funded under Part A or B (formerly Title I
or II). Receipt of RWP support was thus identified at the facility
level; no determination was made at the patient level as to whether
RWP resources supported specific aspects of that patient’s care
(such as provision of antiretroviral drugs). HIV care facilities were
sampled, using probability proportional to size of the patient
population, within size, urban/rural, and RWP-support strata. For
this analysis, we excluded five facilities in Louisiana that provided
only inpatient care, because the RWP is designed to pay for
outpatient care.
From each eligible participating HIV care facility sampled, the
health department requested information about the number and
demographic characteristics of patients who had been seen in the
facility at least once for care for HIV infection during 1998. The
numbers of patients were obtained at the facility level, such that if
multiple HIV clinicians were practicing in a facility that share a
common medical records system, only one tally of patients would
be obtained for the whole facility. Based on this information,
patients were stratified within facilities on race and sex, and
sampled using systematic sampling within strata from an ordered
list. The sampling interval was varied in different race/sex strata to
ensure adequate representation of women and racial/ethnic
minorities. Of note, we did not collect information on other
qualitative aspects of the facilities, such as training or experience
with providing HIV care.
For each sampled patient, medical records were abstracted for
the period January 1–December 31 1998. Abstractors in all study
sites received the same standardized training,and used standardized
definitions for clinical outcomes and laboratory measures. Data
were collected on laboratory values (including CD4+ T-lymphocyte
count and HIV RNA concentration [viral load]); prescription of
highly active antiretroviral therapies (HAART) and prophylactic
medications for the prevention of Pneumocystis jirovecii pneumonia
(PCP) and Mycobacterium avium complex (MAC); provision of
recommended screening tests (tuberculin skin test, Pap smear) and
influenza vaccination; and information about inpatient hospital
utilization. Using treatment guidelines current in 1998 [6,7],
standard definitions were constructed for which patients were
eligible for recommended care (e.g., PCP prophylaxis for patients
with a CD4 count ,200 cells/mL). Details of the definitions for
recommended care are included in Appendix S1. Quality assurance
procedures (e.g., independent re-abstraction of a small sample of
records and/or computerized checksthat data were valid [within an
expected range]) were implemented in all study areas.
Sampling weights were constructed for each patient by
multiplying the sampling weight of the facility by the sampling
weight of the patient within the facility. Further details of sampling
weights and calculation of variance have been previously reported
[5]. These weights were used to estimate the number of patients in
care within the geographic areas, as well as the number of patients
in care at facilities supported by HRSA and at other facilities. For
each geographic area, the proportion of eligible patients receiving
care according to treatment guidelines, with 95% confidence
intervals, was estimated. Statistically significant differences be-
tween proportions were determined using x
2 tests. For some
outcomes such as number of laboratory tests performed within a
time period, the median number of tests per unit time, with 95%
confidence intervals, was estimated; median-split x
2 tests were
used to test for significant differences between medians. All
analyses were performed in SUDAAN to account for the complex
sampling design.
The SHDC project was considered to be non-research by the
Centers for Disease Control and Prevention Institutional Review
Board (IRB), and as such did not require IRB review. Of the three
participating state and local health departments, the protocol was
reviewed and received Institutional Review Board (IRB) approval
in two, and in one, it was determined to be exempt from IRB
review.
Results
Overall, 95% (41/43) of eligible sampled health care facilities
agreed to participate in the survey (range by site: 86%–100%).
Information was abstracted from the medical records of 831
patients (range by site: 169–374); of these, 250 patients (30%)
received their care in facilities supported by the RWP (range by
site: 43–131: 20%–45%). Using weighted sums of patients in care,
we estimated that our study made statistical inference to 18,720
patients in care for HIV infection: 8,490 (45%, CI=29%–62%) in
care at RWP-supported facilities, and 10,230 (55%, CI=37%–
71%) in care at facilities not supported by the RWP.
Limited information was collected about the 41 participating
facilities. The proportions of included facilities that were RWP-
supported facilities in Michigan, King County, and Southern
Ryan White-Supported Care
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numbers of patients in care in the RWP-supported facilities in
each of the three areas (1130, 187, 1783) were higher than the
median number of patients in care in the non-RWP facilities (24,
84, 46). There was a trend for larger patients loads in RWP-
supported facilities in Michigan and southern Louisiana (p=0.06
and p=0.07 respectively by median test), but not in King County
(p=0.52). By categorical size of patient load, in Michigan 38% of
facilities had patient loads ,20, 48% had patient loads 20–199,
and 14% had patient loads $200. Corresponding proportions for
Louisiana were 50%, 20%, and 30%, and for King County were
0%, 67%, and 33%.
There were some statistically significant differences in the
demographic and clinical characteristics of persons receiving care
in RWP-supported and non-RWP supported facilities, and these
differences were not consistent in the three study areas (Table 1).
Women in King County were more likely to receive care in RWP-
supported facilities than in non-RWP-supported facilities, whereas
the opposite was true for men. Persons aged 45 years or older in
King County and Louisiana were less likely to receive care in RWP-
supported facilities than in facilities not supported by the RWP,
while the opposite was true for persons aged 25–44. There were
racial/ethnic differences in the proportions of patients receiving
care in RWP-supported and non-RWP-supported facilities in King
County: 66% of patients receiving care in RWP-supported facilities
were white, non-Hispanic, but 82% of patients receiving care in
non-RWP-supported facilities were white, non-Hispanic. There
were also differences in the distribution of risk for HIV acquisition
(southern Louisiana and King County) and clinical stage of disease
(southern Louisiana) between patients receiving care in RWP-
supported facilities and those receiving care in non-RWP-supported
facilities. In Michigan, there were no significant differences in the
demographic characteristics of those receiving care in RWP-
supported and non-RWP-supported facilities.
For most clinical care outcomes evaluated, there were no
statistically significant differences in the quality of care provided
to patients in RWP-supported and non-RWP-supported facilities
(Table 2). Where statistically significant differences were observed,
in each case, the proportion of patients receiving care according to
treatment guidelines was higher for patients receiving HIV care in
RWP-supported facilities. Patients receiving HIV care in RWP-
supported facilities were more likely to receive indicated PCP or
MAC prophylaxis during 1998 in southern Louisiana; were more
likely to receive a tuberculin skin test during 1998 in King County;
and were more likely to receive a Pap smear in 1998 in all three
study areas. There were no significant differences in the median
number of viral load tests, CD4 counts, or outpatient visits between
patients receiving HIV care at RWP-supported versus non-RWP-
supported facilities in any of the 3 study areas (Table 3). In
Louisiana, patients receiving their HIV care in RWP-supported
facilities were less likely to have had a hospital visit during the year
than patients receiving care in non-RWP supported facilities.
Discussion
We used data from a population-based sample of patients
receiving HIV care in these three geographic areas to describe the
quality of HIV care delivered in 1998 in RWP-supported and non-
RWP-supported facilities. We observed that patients receiving HIV
care at facilities supported thorough RWP funds, administered
directly or indirectly through HRSA, received care which was in
compliance with then-current treatment guidelines at least as often
as patients who received care from non-RWP supported facilities.
We believe the recommended standards of care we evaluated
represent important and objective measures of quality of care, and
are in alignment with HRSA’s currently-proposed clinical perfor-
mance measures [8]. We therefore conclude that care in RWP-
supported facilities was at least of equivalent quality to care
supported by other payers – and in some cases, of higher quality.
The primary strength of our study is that the patients included
wereselected using probability sampling methods,and aretherefore
representative of all patients in care for HIV infection in the three
participating geographic areas. However, our study also had some
weaknesses. In one site, two eligible sampled facilities refused
participation, which, to the extent that the refusing facilities
provided a different quality of care from participating facilities,
could introduce some bias to our findings. In this case, none of the
refusing facilities in the sample of facilities was RWP-supported.
TheKing Countysite had no smallfacilitiesintheir sample. Aswell,
our data are somewhat dated, although we believe that the data are
appropriatefor documenting baseline measures of quality of care by
RWP status, and demonstrating how the Institute of Medicine’s
recommendation to use population-based data to evaluate qualityof
care can be operationalized using data from a population-based,
clinical outcomes surveillance project.
Also, data were only collected about care reflected in the
medical records of the facility where the patient was sampled.
Therefore, for patients who received HIV care in multiple
facilities, the extent to which indicated care was received may
have been underestimated. If patients receiving care in non-RWP-
supported facilities were more likely than those receiving care in
RWP-supported facilities to receive certain services, such as
tuberculin skin tests or Pap smears, outside of the facility where
they were sampled, then our observed differences in the
proportions of patients receiving recommended screening tests
may be due to misclassification. Certain of our data, such as the
low estimate of receipt of viral load tests in Michigan, suggest that
the extent of incomplete data due to this limitation may be
pronounced for some variables in some project sites. This concern
may be especially relevant to the provision of certain services, that
are more likely to be provided by specialists (e.g., Pap tests) or may
be more accessible and less expensive outside of HIV care facilities
(e.g., influenza vaccine). Our analysis of data from women with
HIV infection from a different study indicated that women who
received their gynecological care at the same clinic as their HIV
care were more likely to receive Pap tests as recommended [9].
The designation of RWP-support is somewhat artificial, in that
RWP support was only identified at the facility level. In reality,
some patients may receive support for HIV care which is received
in a facility not directly supported by the RWP. For example,
patients receiving care from private facilities may receive funding
for purchasing medicines through the AIDS Drug Assistance
Program (ADAP). Thus, our data may underestimate the extent of
RWP support for care, but unless receiving ADAP impacted the
care outcomes we analyzed, this should not represent a source of
misclassification bias with respect to our primary conclusions.
In some cases, our precision was low and our statistical power to
detect actual differences may have been limited, even when point
estimates appeared very different. This occurred for two reasons.
For some clinical care outcomes, our survey had large design effects
[5]; for example, the design effect in the Michigan sample for
influenza vaccination was 29.6. In other cases, for example for
MAC prophylaxis in Michigan, there were relatively small numbers
of patients for whom the clinical service was indicated; this also led
to broad confidence intervals and nonsignificant x
2 tests.
HRSA has long-standing quality of care standards, provides
technical assistance to grantees for evaluating quality of care, and has
supported independent evaluations of quality of care in RWP-
Ryan White-Supported Care
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efforts in several ways. For example, data from the HIV Costs and
Services Utilization Study (HCSUS), a nationally representative
sample of patients in care for HIV infection [10], was evaluated to
describe how patients receiving careat RWP-supported facilities were
different from those receiving care in other facilities and evaluated
differencesin the typesofservicesprovided atclinics[11]. They found
that patients in RWP-supported facilities in 1996–1997 were more
likely to be younger, less educated, poorer, female, non-white, and
uninsured. We found similar results with respect to sex, age, and race
in some or all of our sites for care received in 1998. The HCSUS
analysis reported that RWP-supported clinics provided more types of
support services than other clinics[11], but did not report individual
level care outcomes, as we do in our analysis. Other evaluations have
also addressed programmatic issues of service provision at the facility
level, but not at the client level [12].
HRSA has recently taken steps towards development of a client-
level reporting system to capture information on care at the client
level, including supporting pilot activities [13]. However, compa-
rable data from a representative sample of non-RWP-supported
facilities will remain an important point of comparison when
client-level data are reported directly to HRSA in the future.
Other reports have evaluated quality of care within RWP-
supported facilities, but did not have a comparative group of non-
RWP facilities in the same analysis. For example, Wilson et al
conducted an in-depth analysis of quality of care within 68 RWP-
supported facilities, and reported on similar care outcomes as do
we, but further stratified their analyses by provider type. A
separate analysis on the same data suggested that, because clinical
care outcome measures were not highly correlated within facilities,
multiple care outcomes should be evaluated [14]. We evaluated
five of the outcome measures that were identified in that previous
work (HAART prescription, PCP prophylaxis, tuberculosis
screening, cervical cancer screening, and influenza vaccination)
as well as MAC prophylaxis and measures of frequency of CD4
count and HIV viral load tests.
We report data from a public health surveillance project, not
from a health services research study. It is important to recognize
that the view of care offered by a clinical outcomes surveillance
system is necessarily and appropriately different from the view that
Table 1. Estimated characteristics of persons in care for HIV infection by Ryan White Program support status, King County,
Washington, southern Louisiana and Michigan, 1998.
King County (n=288) Southern Louisiana (n=169) Michigan (n=374)
RWP supported
(n=131)
non RWP
supported
(n=157)
RWP supported
(n=43)
non RWP
supported
(n=126)
RWP supported
(n=76)
non RWP
supported
(n=298)
Characteristic Estimated % (SEM) Estimated % (SEM) Estimated % (SEM) Estimated % (SEM) Estimated % (SEM) Estimated % (SEM)
Sex
Male 82.1 (2.3)
* 92.1 (2.8) 68.1 (3.8) 75.3 (4.0) 67.1 (8.5) 72.7 (3.3)
Female 17.9 (2.3) 7.9 (2.8) 31.9 (3.8) 24.7 (4.0) 32.9 (8.5) 27.3 (3.3)
Age
13–24 1.9 (0.9)
{ 2.7 (1.7) 6.5 (5.1)
* 9.8 (3.0) 5.1 (3.2) 3.1 (1.4)
25–44 87.8 (3.4) 63.9 (3.7) 85.2 (3.7) 59.0 (6.3) 64.0 (0.9) 71.0 (3.9)
45+ 10.3 (3.3) 33.4 (4.1) 8.3 (1.4) 31.2 (5.9) 30.9 (2.8) 25.9 (2.9)
Race
White, non-Hispanic 66.4 (4.5){ 82.4 (2.7) 30.9 (14.6) 43.6 (4.8) 28.5 (8.1) 35.5 (6.6)
Black, non-Hispanic 18.1 (3.2) 10.5 (1.8) 65.3 (13.4) 48.9 (5.3) 63.1 (10.1) 59.9 (6.1)
All other/unknown 15.5 (3.1) 7.1 (1.6) 3.8 (1.2) 7.5 (3.3) 8.4 (2.0) 4.6 (1.5)
Risk category
MSM 42.0 (5.6) { 58.3 (4.8) 32.1 (15.3){ 33.3 (5.8) 29.1 (9.6) 24.5 (5.2)
MSM/IDU 13.8 (4.3) 7.0 (2.9) 5.2 (0.4) 5.1 (2.6) 6.0 (5.7) 1.9 (1.4)
IDU 9.8 (2.9) 4.4 (3.1) 43.9 (16.9) 8.4 (2.3) 14.6 (4.1) 15.4 (2.4)
HRH 13.7 (2.5) 5.1 (2.0) 10.6 (1.7) 13.0 (3.2) 9.5 (6.7) 8.8 (1.3)
Other/unknown 20.7 (4.7) 25.2 (2.9) 8.2 (0.3) 40.2 (5.3) 40.8 (7.4) 49.4 (5.2)
Clinical/immunological
CD4 0-99 or AIDS-
defining opportunistic
illness
35.7 (5.4) 41.1 (8.9) 19.7 (1.6){ 41.5 (4.5) 45.5 (5.4) 41.0 (2.0)
CD4 100-349 29.3 (5.2) 22.8 (5.7) 43.9 (2.7) 25.3 (4.5) 18.9 (5.6) 10.6 (2.4)
CD4$350 or unknown 35.0 (5.4) 36.1 (4.1) 36.4 (4.4) 33.2 (4.7) 35.6 (9.8) 48.4 (3.1)
RWP=Ryan White Program; SEM=standard error of the mean; MSM=men who have sex with men; IDU=injecting drug user; HRH=high risk heterosexual; CD4=CD4+
T-lymphocyte count, in cells/mL. Indicated p-values are for the overall test for difference and do not necessarily identify the specific levels of the variable that differ
between RWP and non-RWP funded providers.
*p#0.01 for x
2 test comparing patients at RWP and non-RWP funded providers within study site.
{p#0.001 for x
2 test comparing patients at RWP and non-RWP funded providers within study site.
{p#0.05 for x
2 test comparing patients at RWP and non-RWP funded providers within study site.
doi:10.1371/journal.pone.0003250.t001
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study to describe the drivers of compliance with care guidelines
may consider factors such as patient load, number of infectious
disease specialists, sex of provider, and provider training [15–17].
Clinical outcomes surveillance data, on the other hand, seek to
describe differences when they occur–a high level view of quality
and opportunities for improvement in care, regardless of their
underlying drivers. To the extent that differences are suggested by
surveillance data, more in-depth evaluations and research studies
may be needed to suggest steps for quality improvement. The
Institute of Medicine report explicitly recognized that, despite the
fact that measures of quality derived from population-based
systems reflect ‘‘the cumulative effects of many influences’’,
population-based measures are ‘‘essential in monitoring HIV care
… and identifying areas for improvement’’ [3]. These data were
designed to be interpreted for this purpose within the local sites;
therefore we did not combine data across sites in this analysis.
Although we set out to determine whether differences in quality of
care existed for patients in RWP-supported facilities, it is equally
important to recognize that there were important opportunities for
improving quality of care across the practice settings that we included
in our analysis. For example, the proportions of patients receiving
indicated TB screening, influenza vaccination, PCP prophylaxis, and
Pap screening were all relatively low. Separate analyses of patient-
level factors associated with lack of receipt of TB screening [18],
influenza vaccination [19] and PCP prophylaxis [20] have been
recently published from other US clinical outcomes surveillance data.
As well, it has been recently suggested that gaps in recommended
HIV care in the United States may sometimes result from
prioritization of limited resources by health care providers [14].
Again, more specific research is needed to determine whether
observed gaps in compliance with treatment guidelines should be
addressed with more training, better systems to track delivery of
needed care and identify needs at the client level, more resources for
care provision, or a combination of these interventions. Additionally,
new models for care delivery should be evaluated for their ability to
improve delivery of indicated clinical preventive services [21].
The experiences of this pilot project have been used to inform the
development of a nationwide surveillance system of HIV clinical
outcomes and health care, called the Medical Monitoring Project
(MMP)[4].MMP is a nationalprobability sampleof patients incare
for HIV infection, constructed by multi-stage probability sampling
including a probability proportional to size (PPS) sample of states, a
PPS sample of facilities within selected states, and an equal
probability sample of patients within selected facilities [22]. The
sampling strategy in MMP is based on the methods used in SHDC,
but aims to improve these by using equal probability sampling
methods (EPSEM). Based on the findings from this analysis that the
numbers of persons in care at RWP-supported facilities are
considerable,wehave alsodecided thatstratificationofthesampling
frame of facilities on the basis of receipt of RWP funding is not
necessary to obtain a sufficient number of patients receiving care in
RWP-supported facilities in our sample. Therefore, stratification of
the facility sampling frame by RWP support status will not be
included in future sampling designs.
As part of future chart abstractions, in addition to documenting
whether selected facilities were RWP-supported, abstractors will
attempt to document RWP-supported care or services, even when
they are not received in a RWP-supported facility (e.g., ADAP
funding), in order to better document the impact of the provision
of RWP funds to support HIV care and services (information on
ADAP support of an individual patient’s care would only be
informative for receipt of medications, such as PCP or MAC
prophylaxis, or HAART). In addition, MMP will ascertain all
HIV-related care received by abstracting medical records at all
facilities at which HIV-related care was received for each enrolled
patient. Data from the first nationally-representative sample from
MMP will be publicly available in 2009.
Data from clinical outcomes surveillance projects are primarily
used for resource planning, allocation, and prioritization in state
and local health departments [23]. This analysis demonstrates that
data already collected as part of ongoing surveillance efforts may
also be useful for evaluation of quality of care on a population
level. As HRSA moves to develop client-level data systems to
better document the provision of care and services supported by
RWP funds [13], CDC will continue to ensure that population-
based clinical outcomes surveillance data collected by state and
local health departments are measured in ways that are consistent
with publicly available standards for clinical performance
outcomes developed by HRSA. By so doing, CDC will collect
comparable data from non-RWP supported facilities that can
provide a context in which to interpret the quality of care
evaluations conducted by HRSA and its grantees.
Supporting Information
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